US Biopharmaceuticals: The Biotech Brief: Week of June 26, 2026

Research evidence excerpt

US Biopharmaceuticals: The Biotech Brief: Week of June 26, 2026

Upcoming Catalysts:

Exhibit 1: Upcoming catalysts in our coverage universe

A look ahead at key data, decisions, and milestones. See our catalyst tracker for more.

Ticker Date Catalyst

BIIB 2Q Phase 2 readout of oral BTK inhibitor, BIIB091, in MS

KROS 2Q Initiation of phase 2 basket trial of rinvatercept in DMD

SNDX 7/14/2026 R&D Day highlighting late stage revumenib and axatilimab programs

BIIB 7/12-15/2026 Data presentation of BIIB080 at AAIC

Phase 2 SURF302 NMIBC readout (initial thoughts from our Vegas dinner; our SURF-

TYRA 8/2026

302 preview)

Leqembi IQLIK subcutaneous initiation PDUFA (see our takes on the Leqembi PDUFA

BIIB 8/24/2026

extension)

Source: BofA Global Research

BofA GLOBAL RESEARCH

Upcoming/ Ongoing Conferences:

• European Society for Medical Oncology Gastrointestinal Cancers Congress (ESMO

GI): July 1-4; Munich

• Cell & Gene Therapy Summit (CGT): July 6-8; Boston

• International Society for Stem Cell Research Annual Meeting (ISSCR): July 8-11;

Montreal

• International Society on Thrombosis and Hemostasis Congress (ISTH): July 11- 15;

Paris

• Alzheimer’s Association International Conference (AAIC): July 12-15; London

• American Head & Neck Society International Meeting (AHNS): July 18-22; Boston

Recent Research:

• Former FDA Commissioner Scott Gottlieb calls for returning scientific authority in

medical product review to experienced career experts to return the agency to firmer

footing (JAMA Forum, 2026 June).

• Is the 340B drug pricing program at a tipping point? A JAMA viewpoint highlights

growing momentum to replace upfront drug discounts with a rebate model—an

overhaul that could fundamentally reshape funding for providers and raise concerns